/ /

  • linkedin
  • Increase Font
  • Sharebar

    Topical squalamine a promising treatment for RVO-induced ME

    Investigator-initiated trials reduced need for chronic injections

     

    Take home

    A proof-of-concept trial was launched to determine the safety and efficacy of squalamine lactate ophthalmic solution in eyes with macular edema secondary to branch and central retinal vein occlusion.

     

     

    By Michelle Dalton, ELS; Reviewed by John J. Wroblewski, MD

    Chambersburg, PA—Topical squalamine lactate ophthalmic solution, in synergy with intravitreal ranibizumab, may reduce the need for chronic injection therapy in eyes with retinal vein occlusion (RVO)-induced macular edema, said John J. Wroblewski, MD.

    Dr. Wroblewski and Allen YH Hu, MD, both with Cumberland Valley Retina Specialists, Chambersburg, PA, launched a proof-of-concept trial designed to determine the safety and efficacy of squalamine lactate ophthalmic solution in eyes with macular edema secondary to branch and central retinal vein occlusion (BRVO and CRVO, respectively).

    More in this issue:  How femtosecond laser-assisted cataract surgery helps in challenging cases

    “Squalamine eye drops have the potential to significantly advance the treatment of wet age-related macular degeneration (AMD) and RVO through a unique mechanism of action which may provide distinct or additional benefits to the anti-vascular endothelial growth factor (VEGF) agents currently used to treat these patients,” Dr. Wroblewski said.

    Study details

    Dr. Wroblewski initiated the investigator sponsored, single site trial “to determine the biological effect of squalamine lactate ophthalmic solution in eyes with macular edema secondary to BRVO and CRVO,” he said. “Squalamine is known to inhibit multiple protein growth factors and it is now well established that agents with anti-VEGF properties have benefit for patients with RVO and improve visual acuity. The eye-drop formulation of squalamine may provide a non-invasive approach that is more convenient for patients and physicians.”

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results